Heidelberg Pharma AG
Research Heidelberg Pharma AG (HPHA) on Bullrun: market cap EUR 115.09M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHPHA
- ExchangeXETRA
- CountryGermany
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 115.09M
- Financial periodQ1 2026
- RevenueEUR 3.03M
- Net income-EUR 4.28M
- Free cash flow-EUR 6.26M
- Gross margin87.7%
Valuation Snapshot
latest market cap is EUR 115.09M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 115.09M | n/a | n/a | n/a |
About Heidelberg Pharma AG
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally. The company's lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It also develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Heidelberg Pharma AG's market cap?
Heidelberg Pharma AG's market capitalization is EUR 115.09M.
What does Heidelberg Pharma AG do?
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally. The company's lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma.